Back to results
US 11,958,903 B2Granted
Single-domain antibodies against LAG-3 and uses thereof
AssigneeNanjing Legend Biotech Co., Ltd.
InventorsWang Zhang, Shuai Yang, Shu Wu, Chuan-Chu Chou
Life of this patent
Estimating the term…
Abstract
The present application provides anti-LAG-3 constructs comprising a single-domain antibody (sdAb) that specifically recognizes LAG-3. Also provided are methods of making and using these constructs.
Claims23
An anti-lymphocyte activation gene-3 (anti-LAG-3) construct comprising a single-domain antibody (sdAb) specifically recognizing LAG-3, wherein the sdAb comprises any one of the following:
- (a) a complimentary-determining region 1 (CDR1) CDR1 comprising the amino acid sequence of SEQ ID NO:
- 43;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 119;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 195;
- (b) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 70;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 146;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 222;
- (c) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 40;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 116;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 192;
- (d) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 46;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 122;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 198;
- (e) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 54;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 130;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 206;
- (f) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 41;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 117;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 193;
- (g) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 61;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 137;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 213;
- (h) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 42;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 118;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 194;
- (i) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 72;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 148;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 224;
- (j) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 73;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 149;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 225;
- (k) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 39;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 115;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 191;
- (l) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 44;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 120;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 196;
- or
- (m) a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 45;
- a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 121;
- and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 197.
76 more elements
Dependencies are inferred from the claim text.